Evidence map›Paper›PMID 36519785›Full record

ArticleCancer science2023

circEZH2

Zhengzheng Su, Mengni Zhang, Han Luo, Jinjing Zhong, Junya Tan, Yunyi Xu, Xiuyi Pan, Hao Zeng, Ling Nie, Miao Xu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. A novel intronic circular RNA circFGFR1Journal of translational medicine · 2023
    Article
  4. circEZH2Cancer science · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Zhengzheng SuDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Mengni ZhangDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Han LuoDepartment of Thyroid and Parathyroid Surgery, West China Hospital of Sichuan University, Chengdu, China.
Jinjing ZhongDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Junya TanDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Yunyi XuDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Xiuyi PanDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Hao ZengDepartment of Urology, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Ling NieDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Miao XuDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Ni ChenDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Xueqin ChenDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Qiao ZhouDepartment of Pathology and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-5133-1438
Sichuan University · CN

Funding

National Natural Science Foundation of China (NSFC) 81872107National Natural Science Foundation of China (NSFC) 81872108National Natural Science Foundation of China (NSFC) 82273047National Natural Science Foundation of China (NSFC) 82273073PostDoctoral Research Project, West China Hospital, Sichuan University 2020HXBH001Sichuan Science and Technology Program 2020YJ0008Sichuan Science and Technology Program 2021YFS0114Sichuan Science and Technology Program 2021YFS0115
6 · The paper itself

Abstract

The histone methyltransferase enhancer of zeste homolog 2 (EZH2) is overexpressed in a variety of malignancies including prostate cancer (PCa) and may play important roles in tumor progression. Gene copy number gains, enhanced transcription, and a few circRNAs have been reported to upregulate EZH2. It was not known whether EZH2 itself generates circRNAs that promote its own expression. We here report the identification of circEZH2

Indexed as

MicroRNAsProstatic NeoplasmsCell Line, TumorCell ProliferationEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticHumansMalePolycomb Repressive Complex 2ras GTPase-Activating ProteinsRNA, CircularDAB2IP protein, humanEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMicroRNAsMIRN363 microRNA, humanMIRN708 microRNA, humanPolycomb Repressive Complex 2ras GTPase-Activating ProteinsRNA, CircularcircRNAEZH2miRNAprostate cancertumor progression

Identifiers

PMID36519785
PMCPMC10067432
OpenAlexW4311573190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.